See more : Yorhe Fluid Intelligent Control Co., Ltd. (002795.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Reunion Neuroscience Inc. (REUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reunion Neuroscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Renewable Energy Group, Inc. (REGI) Income Statement Analysis – Financial Results
- Munawla Cargo Co. Ltd. (9571.SR) Income Statement Analysis – Financial Results
- Atlantic Lithium Limited (ALL.L) Income Statement Analysis – Financial Results
- First Capital Real Estate Investment Trust (FCR-UN.TO) Income Statement Analysis – Financial Results
- StrikePoint Gold Inc. (SKP.V) Income Statement Analysis – Financial Results
Reunion Neuroscience Inc. (REUN)
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 4.86M | 960.90K | 1.00K |
| Cost of Revenue | 0.00 | 9.15M | 1.54M | 9.40K |
| Gross Profit | 0.00 | -4.29M | -583.43K | -8.40K |
| Gross Profit Ratio | 0.00% | -88.27% | -60.72% | -840.30% |
| Research & Development | 12.98M | 7.31M | 3.42M | 193.19K |
| General & Administrative | 12.96M | 34.48M | 12.06M | 2.63M |
| Selling & Marketing | 0.00 | 3.23M | 1.63M | 305.71K |
| SG&A | 12.96M | 37.72M | 13.69M | 2.93M |
| Other Expenses | 2.02M | 3.71M | 1.34M | 139.98K |
| Operating Expenses | 27.96M | 48.74M | 18.45M | 3.27M |
| Cost & Expenses | 27.96M | 57.89M | 19.99M | 3.28M |
| Interest Income | 691.79K | 425.90K | 51.04K | 2.66K |
| Interest Expense | 17.73M | 1.10M | 303.30K | 22.56K |
| Depreciation & Amortization | 3.23M | 3.60M | 1.39M | 146.32K |
| EBITDA | -17.15M | -49.00M | -17.58M | -3.13M |
| EBITDA Ratio | 0.00% | -1,008.13% | -1,829.88% | -312,585.70% |
| Operating Income | -20.37M | -52.60M | -18.98M | -3.27M |
| Operating Income Ratio | 0.00% | -1,082.27% | -1,974.99% | -327,217.70% |
| Total Other Income/Expenses | -17.73M | 14.50M | -4.14M | 643.85K |
| Income Before Tax | -38.10M | -54.69M | -23.12M | -2.63M |
| Income Before Tax Ratio | 0.00% | -1,125.30% | -2,405.84% | -262,832.40% |
| Income Tax Expense | 28.12M | 1.10M | 303.30K | 22.56K |
| Net Income | -66.22M | -55.79M | -23.42M | -2.65M |
| Net Income Ratio | 0.00% | -1,147.86% | -2,437.41% | -265,088.60% |
| EPS | -5.69 | -4.83 | -3.54 | -0.35 |
| EPS Diluted | -5.69 | -4.83 | -3.54 | -0.35 |
| Weighted Avg Shares Out | 11.64M | 11.55M | 6.61M | 7.60M |
| Weighted Avg Shares Out (Dil) | 11.64M | 11.55M | 6.61M | 7.60M |
Earnings Previews: Constellation Brands, Field Trip Health, NovaGold, Walgreens
The three major U.S. equity indexes closed lower Monday, with the Nasdaq dipping by 0.72%, the S&P 500 sliding 0.3% and the Dow Jones industrials closing down 0.2%.
Field Trip Health Ltd. to Present at the H.C.
TORONTO, June 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's Co-founder and Executive Chairman, Ronan Levy,...
Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET
- Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice - Discloses Receipt Of Nasdaq Non-Compliance With Minimum Price Notice
Field Trip Health Ltd. to Participate in Upcoming Investor Conferences in May 2022
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's management team will participate in two...
Field Trip Health Ltd. to Participate in Upcoming Investor Conferences
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's management team will participate in the...
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q3 2022 - Earnings Call Transcript
Field Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q3 2022 - Earnings Call Transcript
Field Trip Health Posts 330% YoY Increase In Q3 Revenue
Psychedelics-based company Field Trip Health Ltd. (TSX:FTRP) (NASDAQ:FTRP) reported its third fiscal quarter 2022 results for the three months ended December 31, 2021 and provided a business update.
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event
Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube...
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the...
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US...
Source: https://incomestatements.info
Category: Stock Reports